A well-established action of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) is to decrease the biosynthesis of cholesterol by blocking mevalonate synthesis. Statins are widely prescribed agents for cholesterol reduction given the high incidence of cardiovascular disease in hypercholesterolemic individuals.
Statins decrease the incidence of cardiovascular and cerebrovascular events in clinical trials, 1,2 and the risk of myocardial infarction or stroke decreases even in patients with normal or average cholesterol levels. 3, 4 A growing body of clinical and experimental evidence suggests that statins exhibit additional beneficial actions beyond cholesterol reduction. For example, HMG-CoA reductase inhibition improves
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endothelium-dependent coronary vasodilatation in patients after treatment for only 1 month, before any significant reductions in serum cholesterol levels. 5 Moreover, statins increase fibrinolytic activity in animals, 6 thereby strongly suggesting that these inhibitors exert additional beneficial effects through fast-acting, cholesterol-independent mechanisms.
We reported that statins, including simvastatin and lovastatin, upregulate endothelial nitric oxide synthase (eNOS) and enhance cerebral blood flow (CBF). 7, 8 Additionally, both statins protect the brain against experimental stroke when administered prophylactically without lowering serum cho-lesterol. The mechanism is eNOS dependent because the statins do not reduce tissue injury in eNOS-deficient mice.
In the present study we used mevastatin to show that the statins as a general class increase eNOS mRNA and protein levels and protect against stroke damage. We also show that mevastatin demonstrates a different potency compared with previously reported statins. By varying the duration of treatment and dosage we were able to establish a drug treatment window, and we determined that tachyphylaxis does not develop after 1 month of daily mevastatin administration. Finally, we determined that enhanced eNOS mRNA and protein expression corresponded to the protective actions of mevastatin in ischemic brain.
Materials and Methods

Drug Preparation
Mevastatin (Compactin, Sigma) was chemically activated by alkaline hydrolysis, as previously described. 7 Mevastatin powder was prepared by vacuum centrifugation; the drug was reconstituted in 0.1 mol/L phosphate buffer, and pH was adjusted to 7.4.
Drug Administration
Wild-type 129-SV/eVTAcBr male mice (Taconic Farms; weight, 18 to 22 g) and eNOS-deficient male mice 9 (weight, 18 to 22 g) were treated with either mevastatin at a dose of 2 or 20 mg/kg per day or a corresponding concentration of vehicle for 7, 14, or 28 days. The drug was delivered via 7-or 14-day ALZET miniosmotic pumps (Alza Scientific Products) implanted subcutaneously. Pumps were replaced once for 28-day treatments.
Focal Cerebral Ischemia Model
Animals were subjected to transient 2-hour middle cerebral artery occlusion (MCAO) with the use of the intraluminal filament method previously described (nϭ9 to 12 per group). 10 Briefly, mice were anesthetized with 2% halothane and maintained on a mixture of 1% halothane, 70% nitrous oxide, and 30% oxygen via face mask. An 11-mm silicone-coated 8-0 nylon monofilament was introduced into the external carotid artery, navigated into the internal carotid artery, and advanced to the anterior cerebral artery, occluding the origin of the middle cerebral artery (MCA). Laser-Doppler flowmetry (Perimed) at the core of the ischemic territory was used to assess changes in relative CBF (rCBF). After 2 hours in a small animal incubator, the animals were reanesthetized, and the filament was removed. During the surgical procedure, mice were maintained at a core body temperature of 36°C to 37°C via a temperature control unit (FHC).
For a subset of animals the left femoral artery was cannulated for arterial blood pressure measurements and arterial blood gas analysis (Corning 178, CIBA-Corning Diagnostics). For these animals, rCBF was monitored throughout ischemia and for 15 minutes after reperfusion.
Neurological Deficits
Mice were tested for neurological deficits on a scale of 0 (no deficit) to 3 (severe deficit), as previously described, 11 at 2 hours of ischemia and at 22 hours of reperfusion by an observer blinded to the treatment group.
Infarction Assessment
Twenty-two hours after reperfusion, mice were killed, and brains were rapidly removed. Two-millimeter-thick coronal sections of the forebrain were prepared with the use of a mouse brain matrix (RBM-2000C; Harvard Apparatus). Slices were stained with 2% 2,3,5-triphenyltetrazolium chloride (Sigma) dissolved in phosphatebuffered saline 0.1 mol/L, pH 7.4, for 15 minutes at room temperature, and fixed in 10% buffered formalin overnight. The infarct volumes were quantified with the use of an image analysis system (M4, Imaging Research) by an experimenter blinded to the treatment. Infarct volumes were calculated directly by summing the infarct volume of each section 10 or indirectly to correct for brain edema by subtracting the volume of the undamaged ipsilateral hemisphere from the contralateral hemisphere.
Absolute CBF Measurements
Given that it was previously shown that the statins have an effect on CBF in mice, we studied a small group of mice for this effect after chronic treatment. A subset of mice (nϭ6 per group) treated with mevastatin (20 mg/kg) or vehicle was used for the determination of baseline absolute CBF by the [ 14 C]iodoamphetamine indicator fractionation technique. Mice were anesthetized, ventilated, and monitored as described. 12, 13 Thirty minutes after anesthetic stabilization, CBF was determined as described. 13 
Cholesterol Measurement
Serum total cholesterol levels were quantified from blood drawn from the orbital plexus of mice just before euthanasia with the use of the Sigma Diagnostics Cholesterol kit (procedure No. 352, Sigma Diagnostics) and the recommended cholesterol calibrator (No. C 0534) in a spectrophotometric assay.
Semiquantitative Reverse TranscriptionPolymerase Chain Reaction
Aortas were rapidly harvested from the same group of animals used for infarct measurements, frozen in liquid nitrogen, and stored at Ϫ80°C until use. Aortas were collected because increases in aortic eNOS levels have previously been shown to correlate with increases in brain eNOS levels. 8 Total RNA isolation, reverse transcription (RT), and semiquantitative competitive polymerase chain reaction (PCR) for eNOS were performed as previously described. 8 The sense (5Ј-TTCCGGCTGCCACCTGATCCTAA-3Ј) and antisense (5Ј-AACATATGTCCTTGCTCAAGGCA-3Ј) primers amplified a 340-bp fragment of murine eNOS.
Immunoblot Analysis
Aortas were rapidly harvested from mice after euthanasia, frozen in liquid nitrogen, and stored at Ϫ80°C. Pooled aortas (nϭ2) from mevastatin-(20 mg/kg) or vehicle-treated animals were homogenized in ice-cold radioimmunoprecipitation assay lysis buffer and assayed for total protein. Twenty micrograms of total protein for each sample was separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membranes (BioRad) and blocked overnight at 4°C in 5% milk/Tris-buffered saline/0.05% Tween 20. eNOS protein was detected with the use of a polyclonal antibody (Transduction Laboratories) at a concentration of 1:200. A chemiluminescent system (ECL, Amersham Pharmacia Biotech) was used to expose Kodak autoradiographic film. To ensure equivalent protein loading across samples, the membranes were reprobed with a monoclonal antibody to ␣-tubulin.
Statistical Analysis
Data are expressed as meanϮSEM. Unpaired 2-tailed Student's t test or ANOVA with Bonferroni post hoc comparisons (when Ͼ2 groups were involved) was used for statistical analysis. Probability values of Ͻ0.05 were considered statistically significant.
Results
Cerebral Infarct Reduction
Dosage and duration of statin treatment were varied to assess the effects on brain injury. At a dose of 2 mg/kg, mevastatin failed to significantly decrease infarct volume after 14 or 28 days of treatment (Figure 1 ). At 20 mg/kg, both 14 and 28 days of treatment successfully reduced injury by 26% and 37%, respectively, compared with vehicle ( Figure 1) ; in contrast, 7-day pretreatment was not sufficient to reduce infarct size. Correction for brain edema did not alter the results (indirect; 25% and 36% decrease). Since it was previously reported that simvastatin treatment failed to protect eNOS-deficient mice from stroke damage, 8 we administered only the maximal dose to mutants (20 mg/kg mevastatin). Unlike the experience in wild-type mice, no reduction in infarct size was evident after pretreatment.
Neurological Deficits
After 2 hours of ischemia, vehicle-treated animals showed moderate to severe neurological deficits such as circling and loss of the righting reflex; by 24 hours, mild to moderate deficits persisted. Animals treated with 20 mg/kg mevastatin showed better neurological scores at 2 and 24 hours than vehicle-treated mice (PϽ0.05).
Physiological Parameters
Physiological parameters were assessed in animals treated with 20 mg/kg mevastatin or vehicle for 14 days. No significant differences in blood pressure, PaCO 2 , PaO 2 , or pH were apparent between drug-treated and vehicle groups (Table 1). To reduce the likelihood that any differences in histological outcome were due to alterations in the degree of ischemic insult, rCBF was monitored before, during, and after ischemia. Intraischemic rCBF reductions and postischemic reperfusion levels were comparable between vehicle and treated groups, indicating an equivalent relative depth and duration of ischemia.
Serum Cholesterol Levels
Total serum cholesterol levels were reduced after 28 days of treatment with either the 2-or 20-mg/kg dose. Serum cholesterol did not decrease, however, by 7 or 14 days of treatment (Table 2) . Prior reports have also demonstrated lack of effect on cholesterol levels in experimental animals after 2 weeks of statin administration but a reduction of serum cholesterol levels with a longer (4-week) treatment course. 8, 14 eNOS Upregulation
The effect of mevastatin on eNOS messenger RNA and protein was assessed by RT-PCR and Western blotting. An increase in eNOS mRNA after 14 days with daily 20 mg/kg treatment was observed (Figure 2A and 2B) . To determine the time dependence of this effect, eNOS mRNA was compared at 7, 14, and 28 days after administration of 20 mg/kg per day. eNOS mRNA significantly increased at 14 and 28 days (PϽ0.05) ( Figure 2C and 2D) . In addition, a 2-fold increase in eNOS protein was detected by immunoblotting after 14 days of 20 mg/kg treatment ( Figure 3 ).
Absolute CBF
Chronic mevastatin treatment (14 days at 20 mg/kg) raised CBF by 30% to 82Ϯ4 mL/100 g per minute compared with basal CBF in vehicle-treated animals (63Ϯ3 mL/100 g per minute) (PϽ0.05).
Discussion
The chemical class statins increase eNOS mRNA and protein levels, decrease infarct volume, and reduce neurological deficits in nonatherogenic, normocholesterolemic mice. Mevastatin (chemical name compactin), the family member used in the present experiments, protected the brain when given daily for 14 days at 20 mg/kg. Whenever neuroprotection was achieved, eNOS mRNA levels were increased. Moreover, after 28 days of daily treatment, mevastatin continued to increase eNOS expression and protected ischemic brain, thereby arguing against the development of tachyphylaxis. In fact, infarct reduction may have been enhanced. However, mevastatin given at a lower dose (2 mg/kg per day) did not increase eNOS or protect against ischemic injury regardless of the treatment duration.
Serum cholesterol lowering was not necessary for acute stroke protection by statins. Lower serum cholesterol was detected after 28-day pretreatment, whereas infarct reduction was detected after 14 days, at a time when eNOS was upregulated (Figure 1) . Furthermore, eNOS-deficient mice, refractory to statin-induced stroke protection, still showed reduced serum cholesterol levels to an extent similar to that of their wild-type counterparts.
Administering NO precursors or donors reduces infarct size after rat MCAO and raises CBF. [15] [16] [17] The statin mechanism appears to be related. Mevastatin resulted in an increase in eNOS mRNA and protein levels and augmented absolute CBF. The increased CBF is presumably due to decreased vascular resistance, which may also reflect decreased platelet aggregation and/or leukocyte adhesion by NO-dependent mechanisms. 18 A role for other NOS isoforms seems unlikely because NO and its derivative molecules are generally viewed as neurotoxins when generated in large amounts within brain parenchyma, 10 a few exceptions notwithstanding. 19 Furthermore, statins selectively upregulate the eNOS isoform. 8 Hence, the evidence suggests that vascular rather than neuronal mechanisms predominate in the statin neuroprotective effect. Other statin actions may also be relevant, such as upregulation of the fibrinolytic system, 6 enhanced tissue plasminogen activator and decreased plasminogen activator inhibitor mRNA within endothelial cells, and reduced monocyte chemotaxis and inflammatory responses. 14 The present study, however, argues in favor of a predominant role for eNOS upregulation within the vascular endothelium, at least in this experimental ischemia model. Accordingly, animals deficient in eNOS did not show infarct protection even after 28 days of mevastatin treatment in the presence of lower serum cholesterol.
The statin effect may not be unique to the cerebrovasculature since they may also target the coronary arteries and protect against myocardial infarction. Within weeks of administration, statins enhance responsivity of coronary vessels to acetylcholine and increase tissue plasminogen activator activity in endothelial cells, 5, 6 actions that precede any effect on serum cholesterol levels. 5 In cultured endothelial cells, statins upregulate eNOS mRNA and protein and protect against hypoxic insults, indicating that the newly synthesized protein is functionally active. 20 The mechanism of upregulation appears to be posttranscriptional, secondary to enhanced mRNA stability. 20 Our study highlights that all statins are not equipotent in upregulating eNOS and protecting brain against ischemic insults, despite similar K i values against HMG-CoA reductase in vitro. The differences between statins may relate to variable drug penetration into endothelial cells based on differences in lipophilicity. For example, the active form of mevastatin is approximately 8 times less lipophilic than simvastatin, 21 and lovastatin is less lipophilic than simvastatin. 21, 22 Both are consistent with observations that mevastatin and lovastatin were less potent than simvastatin against ischemic injury. 8 Hence, statins with the highest lipophilicity Data are meanϮSEM. Physiological parameters were measured in a subset of mice pretreated with 20 mg/kg mevastatin daily for 14 days. MABP (mean arterial blood pressure), heart rate, rectal temperature, and blood gas determinations (pHa, PaCO 2 , PaO 2 ) were measured at baseline (15 minutes before ischemia), during (1 hour after onset of ischemia), and after (15 minutes after reperfusion) ischemia. rCBF was measured by laser-Doppler flowmetry and is expressed as percentage of baseline. There were no significant differences in any of the variables examined. Data are meanϮSEM. Serum cholesterol level as a function of dose and duration of mevastatin pretreatment is shown. Wild-type SV/129 mice or eNOS-null mice (eNOSϪ/Ϫ) were treated with either 2 or 20 mg/kg per day of mevastatin or vehicle for varying intervals (nϭ6 -9 animals per group). Significant reductions in total cholesterol were observed with 2 and 20 mg/kg per day mevastatin only when it was administered for 28 days.
*PϽ0.05.
and potency provide the greatest degree of eNOS upregulation and infarct protection. Inhibition of the enzyme HMG-CoA reductase depletes downstream isoprenoids such as geranylgeranyl pyrophosphate and farnesyl pyrophosphate. These isoprenoids not only serve as intermediates for cholesterol biosynthesis but modify proteins to facilitate their attachment to cell membranes. For example, HMG-CoA inhibition blocks geranylgeranylation of G-proteins such as Rho GTPases, thereby inhibiting GTPase activity and causing disruption of actin stress fibers. This mechanism has been shown to increase NOS expression in culture 23 and to be relevant to ischemic data in vivo. 24 In conclusion, we demonstrated that mevastatin, a member of the class of drugs that inhibit HMG-CoA reductase, increases eNOS mRNA and protein levels, augments CBF, and reduces cerebral injury after murine MCAO in a cholesterol-independent manner. The relevant target for HMG-CoA reductase inhibition appears to be within the endothelium rather than the liver, as it is for cholesterol reduction. These findings underscore the importance of developing lipophilic enzyme inhibitors that penetrate the endothelium to block downstream steps in the mevalonic pathway. Figure 2 . A, Semiquantitative RT-PCR demonstrating the dose dependence of mevastatin treatment on eNOS upregulation. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a loading control. B, Quantification of the upregulation of eNOS normalized to GAPDH for the 2 treatment dosages displayed in A. Significant increases in the ratio of eNOS/GAPDH mRNA are noted for 14 days of treatment with 20 mg/kg per day for mevastatin but not 2 mg/kg per day. *PϽ0.05. C, Semiquantitative RT-PCR demonstrating the time dependence of mevastatin treatment on eNOS upregulation. GAPDH was used as a loading control. An eNOS-deficient mouse aorta was used to verify the specificity of the PCR reaction. D, Quantification of the upregulation of eNOS normalized to GAPDH for the 3 treatment times displayed in C. Significant increases in the ratio of eNOS/GAPDH mRNA are noted for 14 and 28 days. *PϽ0.05. MWS indicates molecular weight standards; V, vehicle; and KO, knockout. 
Editorial Comment
Clinical trials with HMG-CoA reductase inhibitors (statins) have demonstrated a significant reduction in the incidence of coronary events and coronary mortality in patients at risk for coronary disease. 1,2 Meta-analysis of statins trials has shown a lower risk of ischemic stroke in patients with history of coronary artery disease with average and/or elevated serum cholesterol levels. 3 Statins have also been shown to attenuate the development of atherosclerosis in both coronary and carotid arterial beds. 4 Subgroup analysis of the major statin trials suggests that some of the effects might be due to mechanisms other than cholesterol reduction. 5 Moskowitz's group was among the first to demonstrate that statin may be neuroprotective by causing an increase in eNOS activity in an animal stroke model. 6 This statin action is independent of its cholesterol-lowering effect. 5 The study in the accompanying article, led by Amin-Hanjani and Stagliano in the Moskowitz laboratory, showed that the infarct volume was reduced in animals pretreated for 2 weeks with mevastatin. The observed effect of mevastatin was closely linked to its ability to increase the eNOS content in the aorta. This additional information strengthens the original contention that the neuroprotective effect of statin action is independent of the cholesterol-lowering effect. The authors reaffirmed that the protective role of mevastatin was absent in mice that are deficient in eNOS.
An excessive amount of NO accumulates in the ischemic brain. The exact role of NO in brain injury has been confounded by the existence of 3 different NOS isoforms that may have different roles in cerebral ischemia. eNOS, through the work of the Moskowitz laboratory, has been shown to be salutary, 7 in contrast to the detrimental roles of neuronal NOS 8, 9 or inducible NOS 10 in acute cerebral ischemia. The present study, which uses a lipophilic statin to increase endogenous eNOS, is an elegant way to demonstrate that eNOS is an endogenous protective mechanism in acute cerebral ischemia. Statins selectively increase eNOS activity and may also suppress the activity of other NOS isoforms such as inducible NOS. Thus, statin treatment may be a more desirable therapeutic strategy than other putative neuroprotective agents, such as NO donors or NOS inhibitors, to alter the NO content in the ischemic brain. An important lesson regarding the application of statins derived from the results of this study, in which different dosing schedules were used, is that pretreatment with mevastatin is necessary. Mevastatin required a period of 2 weeks to increase aortic eNOS levels and confer a neuroprotective role. Statins may be promising as prophylactic agents for ischemic stroke and are less likely to be efficacious in the acute setting.
In the present study mevastatin increased the basal CBF by approximately 30%, presumably through increasing eNOS activity in the endothelium. However, the reduction in CBF after suture MCAO was not different between the control and mevastatin treatment groups. This is somewhat unexpected
